Haixia Cai

Beta-blockers after myocardial infarction with preserved or mildly reduced ejection fraction: existing evidence, knowledge gaps, and an EF-stratified framework

Shujuan Zhao, Chiwei Guo, Haixia Cai, Lei Wang

Background For several decades, beta-blockers (BBs) have served as a cornerstone in the secondary prevention following myocardial infarction (MI). However, contemporary randomized evidence has challenged the long-term BB use in patients with preserved or mildly reduced left ventricular ejection fraction (LVEF) in …

cn (code pays fourni par la source)

Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and VigiAccess databases

Lei Wang, Haixia Cai, Shujuan Zhao

BACKGROUND: Antiplatelet therapy is a cornerstone in the management of atherosclerotic cardiovascular disease. However, the risk profile of central nervous system (CNS) hematomas associated with antiplatelet agents remains incompletely characterized. METHODS: We analyzed CNS-related hematoma adverse event (hAE) reports across the four …

cn (code pays fourni par la source)

Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006–december 2024)

Haixia Cai, Beixi Jia, Zhiyu Song, Lei Wang et autres

OBJECTIVES: While the adjuvanted recombinant zoster vaccine (RZV) is preferred for herpes zoster (HZ) prevention due to its superior efficacy, emerging evidence suggests a potentially elevated reactogenicity risk relative to the live attenuated zoster vaccine (ZVL). This research aims to further assess …

cn (code pays fourni par la source)

Prevalence, risk characteristics, and prediction of low-dose edoxaban treatment in hospitalized patients: a multicenter, observational cohort study

Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni et autres

Background Treatment with a low-dose non-vitamin K antagonist oral anticoagulant (NOAC) is common among hospitalized patients, and a model to predict the need for such treatment would support individualized interventions. This study evaluated the prevalence of low-dose edoxaban treatment and developed and …

cn (code pays fourni par la source)

6-C-methylquercetin in Baeckea frutescens exerts anti-prostate cancer effect via ErbB/PI3K/AKT pathway

Beixi Jia, Mengyao Zhang, Xinyue Jiang, Siyuan Zhou et autres

cn (code pays fourni par la source)

Combining network pharmacology, molecular docking, and experimental verification to investigate the anti-rheumatoid arthritis effect and mechanism of Baeckea frutescens leaves

Xueyang Guo, Mengyao Zhang, Haixia Cai, Xinyue Jiang et autres

The aromatic Baeckea frutescens leaves (BFL) known as “Gang-Song-Cha” is a popular drink (Tea) in South China. To explore the healthcare value, a systematic and in-depth study on BFL alleviating rheumatoid arthritis (RA) was carried out by integrating network pharmacology, molecular docking, …

cn (code pays fourni par la source)

Prevalence, contemporary trends and associated factors of potentially inappropriate prescription of edoxaban in real‐world clinical practice: A subanalysis of the SUNSHINE registry

Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni et autres

AIM: As the direct oral anticoagulant most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated the prevalence of and contemporary trends in edoxaban prescription among Chinese patients as well as factors associated with its …

cn (code pays fourni par la source)

Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database

Haixia Cai, Beixi Jia, Zhonghua Fu, Boya Chen et autres

BACKGROUND: The triglyceride-lowering drug, icosapent ethyl (IPE), was granted a new indication for the reduction of atherosclerotic cardiovascular disease risk in 2019. This study aimed to investigate the safety profile of IPE by mining the FDA Adverse Event Reporting System (FAERS) database. …

cn (code pays fourni par la source)

Prevalence, Contemporary Trends and Associated Factors of Potentially Inappropriate Prescription of Edoxaban in Real-world Clinical Practice: A Subanalysis of the SUNSHINE Registry

Shujuan Zhao, Hengfen Dai, Jiaxin Chen, Ming Ni et autres

Aim: As the non-vitamin K antagonist oral anticoagulant (NOAC) most recently approved in China, data pertaining to clinical edoxaban use are still scarce. This study investigated the prevalence of and contemporary trends in edoxaban prescription among Chinese patients as well as factors …

cn (code pays fourni par la source)

Prevalence, risk factors, and prediction of inappropriate use of non-vitamin K antagonist oral anticoagulants in elderly Chinese patients with atrial fibrillation: A study protocol

Shujuan Zhao, Bo-Ya Chen, Xuejiao Hong, Yinping Liu et autres

Background: Atrial fibrillation (AF) is an arrhythmia that is prevalent globally, and its incidence grows exponentially with aging. Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed in recent years, and it challenges the supremacy of warfarin for thromboembolism prophylaxis in AF. …

cn (code pays fourni par la source)

Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update

Shujuan Zhao, Xuejiao Hong, Haixia Cai, Mingzhou Liu et autres

Combined antithrombotic regimens for atrial fibrillation (AF) patients with coronary artery disease, particularly for those who have acute coronary syndrome (ACS) and/or are undergoing percutaneous coronary intervention (PCI), presents a great challenge in the real-world clinical scenario. Conventionally, a triple antithrombotic therapy …

cn (code pays fourni par la source)

Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration

Shujuan Zhao, Xuejiao Hong, Jingjing Cao, Haixia Cai et autres

Patients with non-valvular atrial fibrillation (NVAF) exhibit a high risk of stroke, which is associated with high mortality. Thus, stroke prevention is crucial for the overall management of NVAF. Two categories of drugs, vitamin K antagonist warfarin and non-vitamin K antagonist oral …

cn (code pays fourni par la source)